Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogue...
October 22 2020 - 7:00AM
Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology
company leveraging its proprietary DNAbilize® liposomal delivery
and antisense technology to develop a portfolio of targeted
nucleic acid cancer drugs, today announced that the United States
Patent and Trademark Office has issued a notice of allowance for
claims related to the Company’s lead product candidate,
prexigebersen, in combination with either a cytidine analogue, such
as decitabine, or the Bcr-Abl tyrosine kinase inhibitors dasatinib
and nilotinib. Prexigebersen is a liposomal formulation containing
the antisense oligodeoxynucleotide targeting growth factor
receptor-bound protein 2 (Grb2).
The new patent, titled, “Combination Therapy with Liposomal
Antisense Oligonucleotides,” (based on Application No. 16/333,221),
will provide broad protection for application of prexigebersen in
the treatment of a variety of cancers in combination with
front-line therapies.
“This further strengthens our intellectual property portfolio
and complements already granted patents. Our growing patent estate
continues to be a valuable asset for Bio-Path as it provides
protection not only for our core product portfolio and research
efforts but now also offers broad protection in combination with
established front-line therapies,” said Peter Nielsen, President
and Chief Executive Officer of Bio-Path Holdings.
“Bio-Path is currently in an ongoing Phase 2 clinical trial of
prexigebersen in combination with decitabine as a treatment for
acute myeloid leukemia (AML), and this new patent protects the
unique therapy combination and supports our ongoing investment in
this program to bring a new treatment option to patients with AML
who have limited treatment options,” added Mr. Nielsen.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi
nanoparticle drugs that can be administered with a
simple intravenous transfusion. Bio-Path’s lead product
candidate, prexigebersen (BP1001, targeting the Grb2 protein),
is in a Phase 2 study for blood cancers and is
under consideration by the FDA to commence Phase 1 studies in
solid tumors. This is followed by BP1002, targeting the Bcl-2
protein, where it is being evaluated in lymphoma and chronic
lymphocytic leukemia (CLL). A third product, BP1001-A, is
finalizing an IND to be evaluated in solid tumor clinical
studies.
For more information, please visit the Company's website at
www.biopathholdings.com.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws. These statements are based on management's current
expectations and accordingly are subject to uncertainty and changes
in circumstances. Any express or implied statements contained in
this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Any statements that are
not historical facts contained in this release are forward-looking
statements that involve risks and uncertainties, including the
impact, risks and uncertainties related to COVID-19 and actions
taken by governmental authorities or others in connection
therewith, Bio-Path’s ability to raise needed additional capital on
a timely basis in order for it to continue its operations,
Bio-Path's ability to have success in the clinical development of
its technologies, the timing of enrollment and release of data in
such clinical studies and the accuracy of such data, limited
patient populations of early stage clinical studies and the
possibility that results from later stage clinical trials with much
larger patient populations may not be consistent with earlier stage
clinical trials, the maintenance of intellectual property rights,
that patents relating to existing or future patent applications
will be issued or that any issued patents will provide meaningful
protection of our drug candidates, risks relating to maintaining
Bio-Path's listing on the Nasdaq Capital Market and such other
risks which are identified in Bio-Path's most recent Annual Report
on Form 10-K, in any subsequent quarterly reports on Form 10-Q and
in other reports that Bio-Path files with the Securities and
Exchange Commission from time to time. These documents are
available on request from Bio-Path Holdings or at www.sec.gov.
Bio-Path disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Investors
Will O’ConnorStern Investor Relations,
Inc.212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path
Holdings, Inc. 832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Apr 2023 to Apr 2024